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Polyarteritis nodosa (PAN) is a systemic vasculitis whose severe forms are treated with glucocorticoids and cyclophosphamide.
Refractory patients are exposed to many complications, notably accelerated atherosclerosis. We report a case report of 71-year-
old man followed for polyarteritis nodosa refractory to glucocorticoids and cyclosphosphamide. Systemic vasculitis relapses are
followed to accelerated atherosclerosis: severe ischemic lesions led to amputation of lower limbs. Remission of refractory PAN is
obtained with rituximab. Disappearance of biological inﬂammatory is allowed to regression of ischemic lesions in upper limbs. In
this situation, we recommend a systematic vascular work-up for patients suﬀered from refractory vasculitis. On the other hand,
therapeutic trials are needed to determine the real eﬃcacy and place of rituximab in the treatment of polyarteritis nodosa.
Copyright © 2009 Emmanuel Ribeiro et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. Presentation
Polyarteritis nodosa (PAN) is a systemic vasculitis of the
medium-sized vessels whose severe form, treated with glu-
cocorticoids and cyclophosphamide, can give rise to late
complications, notably accelerated atherosclerosis, which
remains poorly described in this disease. Remission of
our patient’s severe PAN ﬂare, refractory to conventional
treatment and complicated by accelerated atherosclerosis,
was obtained with rituximab.
2. Assessment
A 71-year-old man, with no remarkable medical history, had
been followed for 2 years for systemic vasculitis with succes-
sive ﬂares manifested by polyarthritis, skin lesions, and bilat-
eral orchitis associated with a biological inﬂammatory syn-
drome without immunological anomalies (no antinuclear
or antineutrophil cytoplasm antibodies (ANCAs) detected).
When a relapse occurred under glucocorticoids, intravenous
cyclophosphamide was started. After two cyclophosphamide
pulses, the patient’s condition deteriorated with subacute
polyarthritis, myalgias, livedo and acrocyanosis of the
four limbs. Signs of sensory-motor polyneuropathy were
observed on electromyograms of the legs. Histological
examinationofaneuromuscularbiopsyfoundvasculitiswith
ﬁbrinoid necrosis compatible with, conﬁrming the diagnosis
of PAN (Figure 1).
Despite intravenous methylprednisolone, an acute coro-
nary syndrome occurred with thrombosis of the right
coronary artery, followed by acute ischemia of the left leg.
Echo-Doppler ultrasonography detected occlusions of the
left anterior and posterior and the right posterior tibial
arteries. Echocardiography found no intracardiac throm-
bus. The persistent biological inﬂammatory syndrome (C-
reactive protein (CRP), 79mg/L) raised the possible risk
of ischemic complications of the vasculitis in the legs. The
ineﬃcacy of conventional therapy led to the prescription of
a weekly rituximab infusion (375mg/m2/ w e e kf o r4w e e k s ) .
The immediate worsening of the ischemic lesions, insensitive2 Case Reports in Medicine
Figure 1: Vasculitis of a muscle arteriole with ﬁbrinoid necrosis
(magniﬁcation: ×250).
to all medical treatments, led to amputation of the lower left
leg. Histopathological examination of the surgical specimen
found atherosclerotic lesions in medium-sized vessels but
no signs of vasculitis or cholesterol emboli, leading us to
suspect accelerated atherosclerosis during a vasculitis ﬂare
in this patient with no known history of cardiovascular or
atheromatous disease.
Rituximab was replaced by mycophenolate mofetil (1g
twice daily) combined with glucocorticoids. The outcome
was favorable, with complete healing of the stump and rapid
regression of the biological inﬂammatory syndrome. He sec-
ondarily developed, independently of any signs of vasculitis,
a suprainfection of the big right toe that deteriorated rapidly.
Despite rituximab being eﬀective, amputation of the second
lower leg was required.
The patient was again hospitalized 6 months later for
necrotic skin lesions on the ﬁngers on the left hand accom-
panied by the reappearance of the biological inﬂammatory
syndrome (CRP, 58mg/L). Echo-Doppler ultrasonography
and arteriography of the arms found atheromatous plaques
in the brachiocephalic trunk and occlusion of the left cubital
and right radial arteries.
The coexistence of medium-sized vessel lesions and
reappearance of the biological inﬂammatory syndrome led
us to suspect a PAN relapse. Rituximab (375mg/m2/week)
was administered for 4 weeks. Rapid and complete healing
of the digital ischemic lesions was observed with regression
of the biological inﬂammatory syndrome (erythrocyte sedi-
mentation rate, 28mm/1sth; CRP, 17mg/L).
Rituximab was continued as maintenance therapy, with
a monthly infusion for 6 months followed by prolongation
of the interinfusion interval to 2 months. At present, after
2 years, the patient is asymptomatic, and no new ischemic
lesions have appeared. He continues to receive rituximab
every 3 months and his general condition is good.
3. Discussion
Rituximabisachimericmonoclonalantibodythatselectively
depletes CD20+ Bl y m p h o c y t e s .I ti sc u r r e n t l yu s e dt ot r e a t
diverse autoimmune diseases and refractory vasculitides:
rheumatoid arthritis (RA), systemic lupus erythematosus
(SLE), Sj¨ ogren’s syndrome, ANCA-associated vasculitides,
mixed cryoglobulinemias, autoimmune cytopenias and neu-
ropathies, myasthenia gravis, and bullous dermatoses [1].
Rituximab has also been successfully used to treat refractory
Wegener’s granulomatosis (WG) and microscopic polyangi-
itis (MPA) resistant to conventional regimens. Keogh et al.
reported obtaining remissions in their 10 WG and one MPA
patients with rituximab [2].
Two case reports have suggested that rituximab is also
eﬀective against corticosteroid resistant polyarteritis nodosa
[3, 4]. This rituximab eﬃcacy against systemic inﬂammatory
diseases led us to use this biologic twice to treat our
patient’s refractory PAN. It is diﬃcult to explain the precise
role of rituximab in the ﬁrst remission because of the
quasisimultaneous administration of cyclophosphamide and
methylprednisolonepulses.Incontrast,thesecondremission
obtained with rituximab strongly suggests its eﬃcacy at
controlling the vasculitis.
Improved survival of patients whose severe and pro-
gressing systemic vasculitides continue to progress under
maximal immunosuppressive therapy now enables us to
see late complications that have previously been poorly
described, notably the probable occurrence of accelerated
atherosclerosis.
Accelerated atherosclerosis has mainly been studied in
RA and SLE patients. Indeed, RA patients have suﬀered
excess mortality of cardiovascular origin, with standardized
all-cause-mortality ratios of 1.41 for women and 1.51 for
men, and respective cardiovascular values of 2.02 and 1.34
[5]. Indeed, 30% of SLE deaths are of cardiovascular origin
[6], with a relative risk of myocardial infarction multiplied
by 5 [7].
Unlike the autoimmune diseases addressed above, accel-
erated atherosclerosis in systemic vasculitides is rare, because
it has been less studied. After adjustment for cardiovascular
risk factors and CRP, it was recently demonstrated that
small-sized-vessel vasculitides were associated with a higher
frequency of subclinical atheromas [8]. Seyahi et al. [9]
showed that their 30 patients with Takayasu arteritis had a
signiﬁcantly higher rate of subclinical atheromas than SLE
patientsandthehealthycontrols(P<. 001).Inanotherstudy
on 29WG patients, the intima-media thickness, a surrogate
marker of atherosclerosis, was signiﬁcantly (P<. 05) wider
compared to a group of controls with the same cardio-
vascular risk factors [10]. Concerning the pathophysiology
of these lesions, the diﬀuse endothelial dysfunction present
during the course of vasculitides [11] could facilitate the
rapid development of atherosclerosis.
Concerning our patient, distinguishing between acceler-
ated atherosclerosis and the speciﬁc vasculitis involvement
was initially diﬃcult. The histopathological examination of
the amputated limbs conﬁrmed the existence of atheroscle-
rotic lesions of medium-sized vessels with no sign of
associated PAN. It should be noted that the distribution of
atherosclerotic lesions aﬀecting medium-sized vessels was
superimposable on the sites of predilection of inﬂammatory
PAN lesions.Case Reports in Medicine 3
4. Conclusion
Among the new biotherapies potentially active against
vasculitides resistant to conventional treatment, rituximab
is given to treat severe, uncontrolled ANCA-associated
vasculitides but it could also have a role to play in refractory
PAN. Therapeutic trials are needed to determine the real
eﬃcacy and place of rituximab in the treatment of PAN.
In these patients whose life expectancy can be prolonged
by these new therapeutic options, it is possible to observe,
during vasculitis ﬂares, the appearance of potentially life-
threatening accelerated atherosclerosis. The chronic or acute
inﬂammation during vasculitis is probably a key element
in the progression of atheromatous disease [12]. In these
situations, it seems logical to recommend a systematic vascu-
lar work-up for patients with progressive and conventional
treatment-resistant vasculitides.
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